PsyGrid: e-Science to Improve the Understanding and Treatment of People in their First Episode of Psychosis
Lead Research Organisation:
University of Manchester
Department Name: Medical and Human Sciences
Abstract
Establishing an e-community on the basis of the Mental Health Research Network will have as one of its longer term aims a promotion of new ways to engage the public in issues concerning mental health research. Public education and engagement is part of the wider brief of the National Institute for Mental Health (England) and this proposal fits in closely to this.
Technical Summary
Severe mental illness (psychosis) is a major public health challenge. Current health policy has a focus on early intervention in the first episode of psychosis as a way of improving outcomes. The evidence for which interventions are best is patchy. Improving this evidence base is a core rationale for the newly formed Mental Health Research Network (MHRN www.mhrn.info) of the National Institute of Mental Health England. The twin aims of this proposal are:- 1) to establish an e-Science framework and functioning e-community which integrates academic and NHS partners in MHRN, so as to enhance research and development capability in routine mental health service settings; 2) to set up an information system to ascertain and characterise a large, representative cohort of individuals with first episode psychosis to enable hypothesis-driven epidemiological and intervention research, particularly into predicting and preventing adverse outcomes. PsyGrid will provide a flexible e-Science/Grid infrastructure deployed over NHSnet using existing governance arrangements for handling clinical data. We will leverage as much existing e-Science software development as possible, working closely with our e-Science Centres and our industrial partner (Microsoft). The PsyGrid e-Science platform will inform, launch and facilitate future externally-funded, hypothesis-driven research in four priority areas in this field: longitudinal studies of risk and protective factors for long-term outcomes, including aetiological inquiry; clinical trials in early psychosis; biological studies of the nature of clinical progression; and new methodologies for evidence-based service developments.
Publications

Bruno E
(2018)
Wearable technology in epilepsy: The views of patients, caregivers, and healthcare professionals.
in Epilepsy & behavior : E&B

Drake RJ
(2016)
How age and gender predict illness course in a first-episode nonaffective psychosis cohort.
in The Journal of clinical psychiatry

Mahmoud A
(2012)
Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment.
in International journal of psychiatry in clinical practice

Mok PL
(2014)
Longitudinal trajectories of peer relations in children with specific language impairment.
in Journal of child psychology and psychiatry, and allied disciplines

Palmier-Claus J
(2013)
Mood variability predicts the course of suicidal ideation in individuals with first and second episode psychosis.
in Psychiatry research

Palmier-Claus JE
(2012)
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application.
in BMC psychiatry

Palmier-Claus JE
(2012)
Affective variability predicts suicidal ideation in individuals at ultra-high risk of developing psychosis: an experience sampling study.
in The British journal of clinical psychology

Palmier-Claus JE
(2011)
Experience sampling research in individuals with mental illness: reflections and guidance.
in Acta psychiatrica Scandinavica

Palmier-Claus JE
(2013)
Cognitive-self consciousness and metacognitive beliefs: Stress sensitization in individuals at ultra-high risk of developing psychosis.
in The British journal of clinical psychology

Palmier-Claus JE
(2011)
The role of metacognitive beliefs in stress sensitisation, self-esteem variability, and the generation of paranoia.
in Cognitive neuropsychiatry
Description | mhrn |
Geographic Reach | Europe |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | support for mental health research networks |
Description | Lundbeck commercial/academic |
Amount | £237,068 (GBP) |
Organisation | P1vital Consortium |
Sector | Private |
Country | United Kingdom |
Start | 06/2012 |
End | 12/2013 |
Description | P1Vital; Sunovion Ltd |
Amount | £450,000 (GBP) |
Organisation | P1vital Consortium |
Sector | Private |
Country | United Kingdom |
Start | 09/2014 |
End | 03/2016 |
Description | mrc dpfs |
Amount | £400,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2010 |
End | 10/2012 |
Title | First episode psychosis data |
Description | PsyGrid was a project that collected data from patients suffering from thier first episode of psychosis. Patients were sought, consented and data collected. A body of data now exists collected using many standard assessment forms. |
Type Of Material | Database/Collection of Data/Biological Samples |
Provided To Others? | No |
Impact | In progress - data collection at follow up finishes may 2010 |
Title | OpenCDMS |
Description | OpenCDMS is a clinical data collection tool that allows the accurate and secure gathering of data for service evlauation or research purposes. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2007 |
Provided To Others? | Yes |
Impact | Many studies both within and outside of MRC funding now use the software: including the Mental Health Research Network for mostof their studies; the Diabetes Research Network; and several independant studies. The use of validation and provenance has proved to be very useful to all of these organisations. |
Description | NIHR Diabetes Research Network |
Organisation | National Institute for Health Research |
Department | NIHR Diabetes Research Network |
Country | United Kingdom |
Sector | Public |
PI Contribution | Project support |
Collaborator Contribution | First actual demonstration that the software tool could be used across various fields of research. This was important to the group as it shows the versitiy of the software we create. |
Impact | Multiple project support |
Start Year | 2007 |
Description | NIHR Mental Health Research Network |
Organisation | King's College London |
Department | School of Medicine KCL |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Design and support of Psygrid/OpenCDMS platform |
Collaborator Contribution | Psygrid (Open-CDMS) has become the project management platform for NIHR MHRN and as of Dec 09 hosts 14 large scale externally funded projects and trials.Financial contribution to clinical data collection on large cohort of first episode psychosis patients (n=900) with follow up (Outlook study) |
Impact | Database and project management for MHRN studies |
Description | NIHR Mental Health Research Network |
Organisation | National Institute for Health Research |
Department | INVOLVE |
Country | United Kingdom |
Sector | Public |
PI Contribution | Design and support of Psygrid/OpenCDMS platform |
Collaborator Contribution | Psygrid (Open-CDMS) has become the project management platform for NIHR MHRN and as of Dec 09 hosts 14 large scale externally funded projects and trials.Financial contribution to clinical data collection on large cohort of first episode psychosis patients (n=900) with follow up (Outlook study) |
Impact | Database and project management for MHRN studies |
Description | Swedish equivalent |
Organisation | Karolinska University Hospital |
Country | Sweden |
Sector | Hospitals |
PI Contribution | Data from our study has been compared with theirs |
Collaborator Contribution | data |
Impact | None yet |
Start Year | 2012 |
Title | OpenCDMS |
Description | Software for managing clinical data arising from studies and trials |
IP Reference | |
Protection | Copyrighted (e.g. software) |
Year Protection Granted | |
Licensed | Yes |
Impact | Improve data quality and security. |
Title | Minocycline |
Description | Clinical trial of minocycline added to treatment as usual for early schizophrenia primary efficacy end point - improvement of negative symptoms over 12 months; primary mechanistic end point - prevention of grey matter loss using imaging in early psychosis. 207 patients recruited within 24 months to target and on time |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2016 |
Development Status | Closed |
Clinical Trial? | Yes |
Impact | The results are being analysed |
URL | http://www.isrctn.com/ISRCTN49141214 |
Description | European Congress of Psychiatry. Madrid |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 100 plus professional |
Year(s) Of Engagement Activity | 2016 |
Description | conference presentations |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | conference presentations |
Year(s) Of Engagement Activity | 2007,2008,2009 |